Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2866097,spectral dissociation constant (Ks),"Cimetidine induced binding changes with a spectral dissociation constant (Ks) of 0.87 mM, whereas famotidine produced no measurable spectral alteration in concentrations up to 4 mM.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),mM,0.87,1804,DB00927,Famotidine
,2866097,elimination half-life (t1/2,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,45.6,1805,DB00927,Famotidine
,2866097,total plasma clearance (CL,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [kg·min],0.28,1806,DB00927,Famotidine
,2866097,t1/2,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,39.0,1807,DB00927,Famotidine
,2866097,CL,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [kg·min],0.31,1808,DB00927,Famotidine
,2866097,t1/2,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,2.9,1809,DB00927,Famotidine
,2866097,t1/2,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,3.0,1810,DB00927,Famotidine
,2866097,renal clearance (CLR),"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],436,1811,DB00927,Famotidine
,2866097,renal clearance (CLR),"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],443,1812,DB00927,Famotidine
,2866097,CLR,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],195,1813,DB00927,Famotidine
,2866097,CLR,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],212,1814,DB00927,Famotidine
,2903807,t 1/2,"All 'old' and 'new' H2-receptor blockers are eliminated relatively rapidly (t 1/2 ranges from 1.5 to 4 hours), mainly by the renal route (glomerular filtration and tubular secretion).",Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903807/),h,1.5 to 4,6283,DB00927,Famotidine
,1442047,cumulative dissolution rate,"An automated dissolution test system was used for the determination of the dissolution rate of famotidine tablets, and a mean cumulative dissolution rate of 97.40 +/- 0.31% in 15 min was obtained.",[Dissolution rate and bioavailability of famotidine tablets]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442047/),%,97.40,10205,DB00927,Famotidine
,1442047,T1/2,"According to a statistic moment algorithm, the results of calculation showed that T1/2 = 2.92 h and Frel = 118.8%.",[Dissolution rate and bioavailability of famotidine tablets]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442047/),h,2.92,10206,DB00927,Famotidine
,1442047,Frel,"According to a statistic moment algorithm, the results of calculation showed that T1/2 = 2.92 h and Frel = 118.8%.",[Dissolution rate and bioavailability of famotidine tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442047/),%,118.8,10207,DB00927,Famotidine
,22147077,dose,"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],1.47,11921,DB00927,Famotidine
,22147077,AUC(0-4),"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],1.47,11922,DB00927,Famotidine
,22147077,AUC(0-4),"The only variable factor, the dasatinib dose-adjusted AUC(0-4) for patients administered an H2RA or PPI, was significantly lower than for patients not administered an acid suppressant (median (quartile 1-quartile 3) values: 1.47 (0.79-2.29) versus 3.51 (2.50-5.45) ng h/mL/mg, respectively, P = 0.0008).",Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22147077/),[h·ng] / [mg·ml],3.51,11923,DB00927,Famotidine
,2896129,renal clearance,"The renal clearance of famotidine averaged 4.43 ml/min/kg (310 ml/min) in normal young volunteers, which exceeded the mean creatinine clearance 1.55 ml/min/kg (109 ml/min), suggesting net secretion is a significant mechanism for elimination of famotidine.",Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896129/),[ml] / [kg·min],4.43,12734,DB00927,Famotidine
,2892544,Plasma clearance,Plasma clearance averaged 463 ml min-1.,Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892544/),[ml] / [min],463,14371,DB00927,Famotidine
,2892544,Renal clearance,"Renal clearance averaged 310 ml min-1, which exceeded the glomerular filtration rate.",Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892544/),[ml] / [min],310,14372,DB00927,Famotidine
,2892544,Urinary recovery of unchanged drug,Urinary recovery of unchanged drug following intravenous administration was about 67 per cent.,Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892544/),%,67,14373,DB00927,Famotidine
,2892544,plasma half-life,Famotidine plasma half-life was approximately 2.6 h.,Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892544/),h,2.6,14374,DB00927,Famotidine
,2892544,bioavailability,The bioavailability averaged 43 per cent of the dose.,Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892544/),%,43,14375,DB00927,Famotidine
,8237405,T1/2Ke,"The T1/2Ke of Fam A and B forms = 3.06 and 3.48 h, Tmax = 2.96 and 2.68 h, The Cmax = 115 and 145 ng.",[Pharmacokinetics and pharmacodynamics of two morphologically homogenous forms of famotidine per os in Chinese healthy volunteers]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237405/),h,3.06,17731,DB00927,Famotidine
,8237405,T1/2Ke,"The T1/2Ke of Fam A and B forms = 3.06 and 3.48 h, Tmax = 2.96 and 2.68 h, The Cmax = 115 and 145 ng.",[Pharmacokinetics and pharmacodynamics of two morphologically homogenous forms of famotidine per os in Chinese healthy volunteers]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237405/),h,3.48,17732,DB00927,Famotidine
,8237405,Tmax,"The T1/2Ke of Fam A and B forms = 3.06 and 3.48 h, Tmax = 2.96 and 2.68 h, The Cmax = 115 and 145 ng.",[Pharmacokinetics and pharmacodynamics of two morphologically homogenous forms of famotidine per os in Chinese healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237405/),h,2.96,17733,DB00927,Famotidine
,8237405,Tmax,"The T1/2Ke of Fam A and B forms = 3.06 and 3.48 h, Tmax = 2.96 and 2.68 h, The Cmax = 115 and 145 ng.",[Pharmacokinetics and pharmacodynamics of two morphologically homogenous forms of famotidine per os in Chinese healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237405/),h,2.68,17734,DB00927,Famotidine
,8237405,Cmax,"The T1/2Ke of Fam A and B forms = 3.06 and 3.48 h, Tmax = 2.96 and 2.68 h, The Cmax = 115 and 145 ng.",[Pharmacokinetics and pharmacodynamics of two morphologically homogenous forms of famotidine per os in Chinese healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237405/),ng,115,17735,DB00927,Famotidine
,8237405,Cmax,"The T1/2Ke of Fam A and B forms = 3.06 and 3.48 h, Tmax = 2.96 and 2.68 h, The Cmax = 115 and 145 ng.",[Pharmacokinetics and pharmacodynamics of two morphologically homogenous forms of famotidine per os in Chinese healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237405/),ng,145,17736,DB00927,Famotidine
,8237405,AUC,"ml-1, AUC = 811 and 1190 h.ng.",[Pharmacokinetics and pharmacodynamics of two morphologically homogenous forms of famotidine per os in Chinese healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237405/),h·ng,811,17737,DB00927,Famotidine
,8237405,AUC,"ml-1, AUC = 811 and 1190 h.ng.",[Pharmacokinetics and pharmacodynamics of two morphologically homogenous forms of famotidine per os in Chinese healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237405/),h·ng,1190,17738,DB00927,Famotidine
,32353682,detection limit,"Hence, the RPLC method was adopted and validated adhering to the FDA guidelines showing excellent linearity for FAM (1.0-20.0 μg/mL) with a detection limit of 0.14 μg/mL.",Pentabromobenzyl-RP versus triazole-HILIC columns for separation of the polar basic analytes famotidine and famotidone: LC method development combined with in silico tools to follow the potential consequences of famotidine gastric instability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32353682/),[μg] / [ml],0.14,21001,DB00927,Famotidine
,32353682,rate constant,The kinetic study of the gastric degradation of FAM in SGJ demonstrated pseudo-first order reaction with a rate constant of 8.1 × 10-3 min-1.,Pentabromobenzyl-RP versus triazole-HILIC columns for separation of the polar basic analytes famotidine and famotidone: LC method development combined with in silico tools to follow the potential consequences of famotidine gastric instability. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32353682/),1/[min],8.1 × 10-3,21002,DB00927,Famotidine
,26597253,unbound concentrations,"Famotidine unbound concentrations in plasma reached 1 µM, thus exceeding the in vitro concentrations that inhibit MATE1 [concentration of drug producing 50 % inhibition (IC50) 0.25 µM].","The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597253/),μM,1,21669,DB00927,Famotidine
,26597253,concentration of drug producing 50 % inhibition (IC50),"Famotidine unbound concentrations in plasma reached 1 µM, thus exceeding the in vitro concentrations that inhibit MATE1 [concentration of drug producing 50 % inhibition (IC50) 0.25 µM].","The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597253/),μM,0.25,21670,DB00927,Famotidine
>,26597253,"maximum unbound plasma drug concentration (C max,u)/IC50","Based on current regulatory guidance, these concentrations are expected to inhibit MATE1 clinically [i.e. maximum unbound plasma drug concentration (C max,u)/IC50 >0.1].","The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597253/),,0.1,21671,DB00927,Famotidine
,9824781,elimination half-life (t1/2),"From the intravenous data, the mean +/- standard deviation elimination half-life (t1/2) was 2.11 +/- 0.75 hours, the total clearance (Cl) was 0.79 +/- 0.41 L/kg/hr, the renal clearance was 0.57 +/- 0.26 L/kg/hr, the fraction eliminated unchanged in the urine was 83% +/- 16%, and the apparent volume of distribution (Vdss) was 1.33 +/- 0.53 L/kg.",Pharmacokinetics of famotidine in patients with cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824781/),h,2.11,24689,DB00927,Famotidine
,9824781,total clearance (Cl),"From the intravenous data, the mean +/- standard deviation elimination half-life (t1/2) was 2.11 +/- 0.75 hours, the total clearance (Cl) was 0.79 +/- 0.41 L/kg/hr, the renal clearance was 0.57 +/- 0.26 L/kg/hr, the fraction eliminated unchanged in the urine was 83% +/- 16%, and the apparent volume of distribution (Vdss) was 1.33 +/- 0.53 L/kg.",Pharmacokinetics of famotidine in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824781/),[l] / [h·kg],0.79,24690,DB00927,Famotidine
,9824781,renal clearance,"From the intravenous data, the mean +/- standard deviation elimination half-life (t1/2) was 2.11 +/- 0.75 hours, the total clearance (Cl) was 0.79 +/- 0.41 L/kg/hr, the renal clearance was 0.57 +/- 0.26 L/kg/hr, the fraction eliminated unchanged in the urine was 83% +/- 16%, and the apparent volume of distribution (Vdss) was 1.33 +/- 0.53 L/kg.",Pharmacokinetics of famotidine in patients with cystic fibrosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824781/),[l] / [h·kg],0.57,24691,DB00927,Famotidine
,9824781,fraction eliminated unchanged in,"From the intravenous data, the mean +/- standard deviation elimination half-life (t1/2) was 2.11 +/- 0.75 hours, the total clearance (Cl) was 0.79 +/- 0.41 L/kg/hr, the renal clearance was 0.57 +/- 0.26 L/kg/hr, the fraction eliminated unchanged in the urine was 83% +/- 16%, and the apparent volume of distribution (Vdss) was 1.33 +/- 0.53 L/kg.",Pharmacokinetics of famotidine in patients with cystic fibrosis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824781/),%,83,24692,DB00927,Famotidine
,9824781,apparent volume of distribution (Vdss),"From the intravenous data, the mean +/- standard deviation elimination half-life (t1/2) was 2.11 +/- 0.75 hours, the total clearance (Cl) was 0.79 +/- 0.41 L/kg/hr, the renal clearance was 0.57 +/- 0.26 L/kg/hr, the fraction eliminated unchanged in the urine was 83% +/- 16%, and the apparent volume of distribution (Vdss) was 1.33 +/- 0.53 L/kg.",Pharmacokinetics of famotidine in patients with cystic fibrosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824781/),[l] / [kg],1.33,24693,DB00927,Famotidine
,9824781,bioavailability,The bioavailability determined from comparison of intravenous and oral area under the curve data was 71% +/- 27%.,Pharmacokinetics of famotidine in patients with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824781/),%,71,24694,DB00927,Famotidine
,2864251,AUC0- infinity,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[h·μg] / [ml],38.1,26778,DB00927,Famotidine
,2864251,AUC0- infinity,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[h·μg] / [ml],38.8,26779,DB00927,Famotidine
,2864251,systemic clearance,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [h·kg],0.11,26780,DB00927,Famotidine
,2864251,systemic clearance,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [h·kg],0.16,26781,DB00927,Famotidine
,2864251,half-life,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),h,2.8,26782,DB00927,Famotidine
,2864251,half-life,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),h,2.0,26783,DB00927,Famotidine
,2864251,volume of distribution,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [kg],0.39,26784,DB00927,Famotidine
,2864251,volume of distribution,"Concomitant famotidine administration did not alter any of the pharmacokinetic parameters of theophylline (AUC0- infinity; 38.1 +/- 8.7 vs. 38.8 +/- 6.3 micrograms.hr.ml-1), while cimetidine demonstrated a significant reduction in theophylline systemic clearance (0.11 +/- 0.02 vs. 0.16 +/- 0.02 L/hr/kg; p less than 0.001), a 40% prolongation of half-life (2.8 +/- 0.9 vs. 2.0 +/- 0.5 hr), with no change in the volume of distribution (0.39 +/- 0.1 vs. 0.41 +/- 0.13 L/kg).",Cimetidine versus famotidine: the effect on the pharmacokinetics of theophylline in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864251/),[l] / [kg],0.41,26785,DB00927,Famotidine
,16129921,CD(50),"Astemizole (1 mg/kg) did not affect the threshold for aminophylline-induced seizures, but when administered at a dose of 2 mg/kg, it significantly reduced the CD(50) value of aminophylline from 249 mg/kg to 211 mg/kg (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),[mg] / [kg],249,29195,DB00927,Famotidine
,16129921,CD(50),"Astemizole (1 mg/kg) did not affect the threshold for aminophylline-induced seizures, but when administered at a dose of 2 mg/kg, it significantly reduced the CD(50) value of aminophylline from 249 mg/kg to 211 mg/kg (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),[mg] / [kg],211,29196,DB00927,Famotidine
,16129921,latency to,"Furthermore, astemizole (2 mg/kg) decreased latency to the clonic phase of aminophylline-induced convulsions from 51.1 +/- 4.5 to 32.1 +/- 4.3 min (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),min,51.1,29197,DB00927,Famotidine
,16129921,latency to,"Furthermore, astemizole (2 mg/kg) decreased latency to the clonic phase of aminophylline-induced convulsions from 51.1 +/- 4.5 to 32.1 +/- 4.3 min (p < 0.01).",Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16129921/),min,32.1,29198,DB00927,Famotidine
,18977187,m/z,"Data acquisition was carried out in multiple reaction monitoring (MRM) mode, by monitoring the transitions m/z 307.3-->107.1 for roxatidine and m/z 338.4-->189.1 for famotidine.",Quantification of roxatidine in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18977187/),,307.3,32872,DB00927,Famotidine
,18977187,m/z,"Data acquisition was carried out in multiple reaction monitoring (MRM) mode, by monitoring the transitions m/z 307.3-->107.1 for roxatidine and m/z 338.4-->189.1 for famotidine.",Quantification of roxatidine in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18977187/),,107.1,32873,DB00927,Famotidine
,18977187,m/z,"Data acquisition was carried out in multiple reaction monitoring (MRM) mode, by monitoring the transitions m/z 307.3-->107.1 for roxatidine and m/z 338.4-->189.1 for famotidine.",Quantification of roxatidine in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18977187/),,338.4,32874,DB00927,Famotidine
,18977187,m/z,"Data acquisition was carried out in multiple reaction monitoring (MRM) mode, by monitoring the transitions m/z 307.3-->107.1 for roxatidine and m/z 338.4-->189.1 for famotidine.",Quantification of roxatidine in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18977187/),,189.1,32875,DB00927,Famotidine
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.38,37476,DB00927,Famotidine
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.15,37477,DB00927,Famotidine
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.13,37478,DB00927,Famotidine
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.05,37479,DB00927,Famotidine
,28801980,IC50,"Moreover, in vitro experiments demonstrated that PPIs (esomeprazole, lansoprazole, omeprazole and rabeprazole) inhibited hOAT3-mediated uptake of MTX in a concentration-dependent manner (IC50 values of 0.40-5.5 μ m), with a rank order of lansoprazole > esomeprazole > rabeprazole > omeprazole.",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),m·μ,0.40-5.5,37480,DB00927,Famotidine
,2902874,elimination half-life,3. A 7 to 10 fold prolongation of famotidine's elimination half-life (27.2 +/- 8.5 h; mean +/- s.d.) was observed in patients with renal failure as compared with the half-life (2.6-3.6 h) in subjects with normal renal function.,Pharmacokinetics and dynamics of famotidine in patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2902874/),h,27.2,41460,DB00927,Famotidine
,2902874,half-life,3. A 7 to 10 fold prolongation of famotidine's elimination half-life (27.2 +/- 8.5 h; mean +/- s.d.) was observed in patients with renal failure as compared with the half-life (2.6-3.6 h) in subjects with normal renal function.,Pharmacokinetics and dynamics of famotidine in patients with renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2902874/),h,2.6-3.6,41461,DB00927,Famotidine
,2902874,Total body clearance (CL),"4. Total body clearance (CL) and volume of distribution (V) were found to be 33.5 +/- 10.1 ml min-1 and 1.3 +/- 0.7 l kg-1, respectively in patients with end-stage renal failure.",Pharmacokinetics and dynamics of famotidine in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2902874/),[ml] / [min],33.5,41462,DB00927,Famotidine
,2902874,volume of distribution (V),"4. Total body clearance (CL) and volume of distribution (V) were found to be 33.5 +/- 10.1 ml min-1 and 1.3 +/- 0.7 l kg-1, respectively in patients with end-stage renal failure.",Pharmacokinetics and dynamics of famotidine in patients with renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2902874/),[l] / [kg],1.3,41463,DB00927,Famotidine
,1673880,oral bioavailability,The mean oral bioavailability for the H2-antagonists ranges from 50 to 70%.,Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),%,50 to 70,45683,DB00927,Famotidine
,1673880,terminal half-life,"All of the H2-antagonists are eliminated quite rapidly, with a terminal half-life of 1 to 3h and a total body clearance of 24 to 48 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),h,1 to 3,45684,DB00927,Famotidine
,1673880,total body clearance,"All of the H2-antagonists are eliminated quite rapidly, with a terminal half-life of 1 to 3h and a total body clearance of 24 to 48 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),[l] / [h],24 to 48,45685,DB00927,Famotidine
,1673880,renal clearances,"Elimination is mainly attributable to renal excretion, with renal clearances ranging from 13.8 to 30 L/h.",Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673880/),[l] / [h],13.8 to 30,45686,DB00927,Famotidine
,2861096,volume of distribution at steady state,The volume of distribution at steady state was 1.141/kg in normal subjects and was not altered in renal failure.,"Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861096/),1/[kg],1.141,46649,DB00927,Famotidine
,2861096,half-life of elimination,"The half-life of elimination was 2.59 h in normal subjects and was unchanged in mild renal failure (creatinine clearance, CLCR 90-60 ml/min/1.48 m2) but was increased to 4.72 h in moderate renal failure (CLCR 60-30 ml/min/1.48 m2), and to 12.07 h in severe renal failure (CLCR below 30 ml/min/1.48 m2).","Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861096/),h,2.59,46650,DB00927,Famotidine
,2861096,half-life of elimination,"The half-life of elimination was 2.59 h in normal subjects and was unchanged in mild renal failure (creatinine clearance, CLCR 90-60 ml/min/1.48 m2) but was increased to 4.72 h in moderate renal failure (CLCR 60-30 ml/min/1.48 m2), and to 12.07 h in severe renal failure (CLCR below 30 ml/min/1.48 m2).","Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861096/),h,4.72,46651,DB00927,Famotidine
,2861096,half-life of elimination,"The half-life of elimination was 2.59 h in normal subjects and was unchanged in mild renal failure (creatinine clearance, CLCR 90-60 ml/min/1.48 m2) but was increased to 4.72 h in moderate renal failure (CLCR 60-30 ml/min/1.48 m2), and to 12.07 h in severe renal failure (CLCR below 30 ml/min/1.48 m2).","Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861096/),h,12.07,46652,DB00927,Famotidine
,8513846,half-life,"The half-life of famotidine was 3.8 h, the total plasma clearance was 297 ml.min-1, and a steady state volume of distribution of 1.2 l.kg-1 was found.",Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513846/),h,3.8,67449,DB00927,Famotidine
,8513846,total plasma clearance,"The half-life of famotidine was 3.8 h, the total plasma clearance was 297 ml.min-1, and a steady state volume of distribution of 1.2 l.kg-1 was found.",Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513846/),[ml] / [min],297,67450,DB00927,Famotidine
,8513846,steady state volume of distribution,"The half-life of famotidine was 3.8 h, the total plasma clearance was 297 ml.min-1, and a steady state volume of distribution of 1.2 l.kg-1 was found.",Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513846/),[l] / [kg],1.2,67451,DB00927,Famotidine
,1354432,maximum concentrations,The maximum concentrations were 1.19 +/- 0.32 mg/liter after 0.1 g of cefpodoxime proxetil and 2.54 +/- 0.64 mg/liter after 0.2 g of cefpodoxime proxetil.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),[mg] / [l],1.19,68026,DB00927,Famotidine
,1354432,maximum concentrations,The maximum concentrations were 1.19 +/- 0.32 mg/liter after 0.1 g of cefpodoxime proxetil and 2.54 +/- 0.64 mg/liter after 0.2 g of cefpodoxime proxetil.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),[mg] / [l],2.54,68027,DB00927,Famotidine
,1354432,elimination half-lives,The elimination half-lives were 149 min for 0.1 g and 172 min for 0.2 g of cefpodoxime proxetil.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),min,149,68028,DB00927,Famotidine
,1354432,elimination half-lives,The elimination half-lives were 149 min for 0.1 g and 172 min for 0.2 g of cefpodoxime proxetil.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),min,172,68029,DB00927,Famotidine
,1354432,AUC,Combination with Maalox 70 caused a reduction in the AUC from 14.0 +/- 3.9 to 8.44 +/- 1.85 mg.h/liter.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),[h·mg] / [l],14.0,68030,DB00927,Famotidine
,1354432,AUC,Combination with Maalox 70 caused a reduction in the AUC from 14.0 +/- 3.9 to 8.44 +/- 1.85 mg.h/liter.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),[h·mg] / [l],8.44,68031,DB00927,Famotidine
,1354432,AUC,"After famotidine, the AUC decreased to 8.36 +/- 2.0 mg . h/liter.",Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),[h·mg] / [l],8.36,68032,DB00927,Famotidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],547,69199,DB00927,Famotidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],531,69200,DB00927,Famotidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],563,69201,DB00927,Famotidine
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],529,69202,DB00927,Famotidine
,1818056,detection limit,"Using ultraviolet detection at 267 nm, the detection limit for plasma famotidine was 5 ng/ml.",Sensitive high-performance liquid chromatographic determination of famotidine in plasma. Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1818056/),[ng] / [ml],5,74880,DB00927,Famotidine
,2905936,half-life,"The half-life of famotidine after oral administration in patients with renal failure was 22.5 hours as opposed to 2.5 hours in control subjects: after intravenous injection, it was 14.6 hours as compared with 2.2 hours.",Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905936/),h,22.5,75920,DB00927,Famotidine
,2905936,half-life,"The half-life of famotidine after oral administration in patients with renal failure was 22.5 hours as opposed to 2.5 hours in control subjects: after intravenous injection, it was 14.6 hours as compared with 2.2 hours.",Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905936/),h,2.5,75921,DB00927,Famotidine
,2905936,half-life,"The half-life of famotidine after oral administration in patients with renal failure was 22.5 hours as opposed to 2.5 hours in control subjects: after intravenous injection, it was 14.6 hours as compared with 2.2 hours.",Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905936/),h,14.6,75922,DB00927,Famotidine
,2905936,half-life,"The half-life of famotidine after oral administration in patients with renal failure was 22.5 hours as opposed to 2.5 hours in control subjects: after intravenous injection, it was 14.6 hours as compared with 2.2 hours.",Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905936/),h,2.2,75923,DB00927,Famotidine
,2905936,bioavailability,The bioavailability after oral administration was 49.4% in patients with renal failure and 55.2% in control subjects.,Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905936/),%,49.4,75924,DB00927,Famotidine
,2905936,bioavailability,The bioavailability after oral administration was 49.4% in patients with renal failure and 55.2% in control subjects.,Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905936/),%,55.2,75925,DB00927,Famotidine
,2905936,elimination rate,"The dialysis elimination rate was stable and independent of its plasma level, with an average of 41.9%.",Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905936/),%,41.9,75926,DB00927,Famotidine
,9821410,trough,"Mean trough and peak concentrations of ITZ without famotidine were 332 ng/ml and 476 ng/ml, respectively.",Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821410/),[ng] / [ml],332,81035,DB00927,Famotidine
,9821410,peak concentrations,"Mean trough and peak concentrations of ITZ without famotidine were 332 ng/ml and 476 ng/ml, respectively.",Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821410/),[ng] / [ml],476,81036,DB00927,Famotidine
,8618369,duration of effect,"However, its duration of effect was only 60 minutes.",Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618369/),min,60,83900,DB00927,Famotidine
,8618369,duration of effect,"However, famotidine had a duration of effect of at least 540 minutes.",Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8618369/),min,540,83901,DB00927,Famotidine
,2569486,peak plasma famotidine concentration,"Ingestion of the antacid concurrently with famotidine resulted in a significant reduction of peak plasma famotidine concentration (from 156 +/- 22 to 104 +/- 7, P less than 0.05) and area under the famotidine plasma concentration curve (from 956 +/- 125 to 607 +/- 56, P less than 0.02).",Impaired bioavailability of famotidine given concurrently with a potent antacid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569486/),,156,89193,DB00927,Famotidine
,2569486,peak plasma famotidine concentration,"Ingestion of the antacid concurrently with famotidine resulted in a significant reduction of peak plasma famotidine concentration (from 156 +/- 22 to 104 +/- 7, P less than 0.05) and area under the famotidine plasma concentration curve (from 956 +/- 125 to 607 +/- 56, P less than 0.02).",Impaired bioavailability of famotidine given concurrently with a potent antacid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569486/),,104,89194,DB00927,Famotidine
,2569486,area under the famotidine plasma concentration curve,"Ingestion of the antacid concurrently with famotidine resulted in a significant reduction of peak plasma famotidine concentration (from 156 +/- 22 to 104 +/- 7, P less than 0.05) and area under the famotidine plasma concentration curve (from 956 +/- 125 to 607 +/- 56, P less than 0.02).",Impaired bioavailability of famotidine given concurrently with a potent antacid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569486/),,956,89195,DB00927,Famotidine
,2569486,area under the famotidine plasma concentration curve,"Ingestion of the antacid concurrently with famotidine resulted in a significant reduction of peak plasma famotidine concentration (from 156 +/- 22 to 104 +/- 7, P less than 0.05) and area under the famotidine plasma concentration curve (from 956 +/- 125 to 607 +/- 56, P less than 0.02).",Impaired bioavailability of famotidine given concurrently with a potent antacid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569486/),,607,89196,DB00927,Famotidine
,19569219,plasma AUC((0-infinity)),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[h·μg] / [ml],32.1,89963,DB00927,Famotidine
,19569219,plasma AUC((0-infinity)),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[h·μg] / [ml],16.8,89964,DB00927,Famotidine
,19569219,plasma AUC((0-infinity)),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[h·μg] / [ml],62.7,89965,DB00927,Famotidine
,19569219,C(max),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[μg] / [ml],4.01,89966,DB00927,Famotidine
,19569219,C(max),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[μg] / [ml],1.70,89967,DB00927,Famotidine
,19569219,C(max),"Geometric mean (95% CI) sulfasalazine plasma AUC((0-infinity)) values were 32.1 (13.2, 78.1), 16.8 (7.15, 39.6) and 62.7 (33.4, 118) microg h/mL, and C(max) were 4.01 (1.62, 9.92), 1.70 (0.66, 4.40), and 6.86 (3.61, 13.0) microg/mL for CC, CA, and AA subjects, respectively.",Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19569219/),[μg] / [ml],6.86,89968,DB00927,Famotidine
,24663504,MTD,The MTD of oral ixabepilone was 25 mg.,A phase I study of oral ixabepilone in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24663504/),mg,25,93317,DB00927,Famotidine
,24663504,half-life,The mean half-life of ixabepilone calculated after day 5 of cycle 1 ranged from 24 to 47 h.,A phase I study of oral ixabepilone in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24663504/),h,24 to 47,93318,DB00927,Famotidine
,24663504,MTD,The MTD of oral ixabepilone when administered once daily for five consecutive days every 21 days was 25 mg.,A phase I study of oral ixabepilone in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24663504/),mg,25,93319,DB00927,Famotidine
,11301560,maximum plasma concentration (Cmax),"The mean +/- standard deviation maximum plasma concentration (Cmax) was 640.66 +/- 250.66 ng/mL, the elimination half-life (t1/2 beta) was 10.51 +/- 5.43 hours, and the apparent volume of distribution at steady state (Vdss) was 0.82 +/- 0.29 L/kg.",Pharmacokinetics and pharmacodynamics of famotidine in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301560/),[ng] / [ml],640.66,102900,DB00927,Famotidine
,11301560,elimination half-life (t1/2 beta),"The mean +/- standard deviation maximum plasma concentration (Cmax) was 640.66 +/- 250.66 ng/mL, the elimination half-life (t1/2 beta) was 10.51 +/- 5.43 hours, and the apparent volume of distribution at steady state (Vdss) was 0.82 +/- 0.29 L/kg.",Pharmacokinetics and pharmacodynamics of famotidine in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301560/),h,10.51,102901,DB00927,Famotidine
,11301560,apparent volume of distribution at steady state (Vdss),"The mean +/- standard deviation maximum plasma concentration (Cmax) was 640.66 +/- 250.66 ng/mL, the elimination half-life (t1/2 beta) was 10.51 +/- 5.43 hours, and the apparent volume of distribution at steady state (Vdss) was 0.82 +/- 0.29 L/kg.",Pharmacokinetics and pharmacodynamics of famotidine in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301560/),[l] / [kg],0.82,102902,DB00927,Famotidine
,11301560,Plasma clearance (Cl),"Plasma clearance (Cl) and renal clearance (ClR) were 0.132 +/- 0.061 L/hr/kg and 0.093 +/- 0.056 L/hr/kg, respectively.",Pharmacokinetics and pharmacodynamics of famotidine in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301560/),[l] / [h·kg],0.132,102903,DB00927,Famotidine
,11301560,renal clearance (ClR),"Plasma clearance (Cl) and renal clearance (ClR) were 0.132 +/- 0.061 L/hr/kg and 0.093 +/- 0.056 L/hr/kg, respectively.",Pharmacokinetics and pharmacodynamics of famotidine in infants. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11301560/),[l] / [h·kg],0.093,102904,DB00927,Famotidine
,2104076,total plasma clearance,"Following intravenous (i.v.) administration, the mean (range) total plasma clearance values were not significantly different in the patients with compensated cirrhosis (n = 7), 337 (241-576) ml/min or in the patients with decompensated cirrhosis (n = 7), 270 (120-408) ml/min compared with the control group, 370 (154-612) ml/min.",Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104076/),[ml] / [min],337,106138,DB00927,Famotidine
,2104076,total plasma clearance,"Following intravenous (i.v.) administration, the mean (range) total plasma clearance values were not significantly different in the patients with compensated cirrhosis (n = 7), 337 (241-576) ml/min or in the patients with decompensated cirrhosis (n = 7), 270 (120-408) ml/min compared with the control group, 370 (154-612) ml/min.",Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104076/),[ml] / [min],270,106139,DB00927,Famotidine
,2104076,total plasma clearance,"Following intravenous (i.v.) administration, the mean (range) total plasma clearance values were not significantly different in the patients with compensated cirrhosis (n = 7), 337 (241-576) ml/min or in the patients with decompensated cirrhosis (n = 7), 270 (120-408) ml/min compared with the control group, 370 (154-612) ml/min.",Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104076/),[ml] / [min],370,106140,DB00927,Famotidine
,2104076,half-life,"The mean half-life in the compensated cirrhotics, 2.86 (1.87-4.98) h, was similar to that in the control group 2.91 (1.86-6.03) h, but it was insignificantly prolonged in the decompensated cirrhotics 3.35 (2.00-5.77) h.",Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104076/),h,2.86,106141,DB00927,Famotidine
,2104076,half-life,"The mean half-life in the compensated cirrhotics, 2.86 (1.87-4.98) h, was similar to that in the control group 2.91 (1.86-6.03) h, but it was insignificantly prolonged in the decompensated cirrhotics 3.35 (2.00-5.77) h.",Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104076/),h,2.91,106142,DB00927,Famotidine
,2104076,half-life,"The mean half-life in the compensated cirrhotics, 2.86 (1.87-4.98) h, was similar to that in the control group 2.91 (1.86-6.03) h, but it was insignificantly prolonged in the decompensated cirrhotics 3.35 (2.00-5.77) h.",Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104076/),h,3.35,106143,DB00927,Famotidine
,2104076,systemic availability,"The mean systemic availability of the drug, estimated from urinary recovery, was 0.39 (0.15-0.64) in the healthy controls, 0.35 (0.14-0.51) in the patients with compensated cirrhosis and 0.38 (0.13-0.77) in the patients with decompensated cirrhosis.",Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104076/),,0.39,106144,DB00927,Famotidine
,2104076,systemic availability,"The mean systemic availability of the drug, estimated from urinary recovery, was 0.39 (0.15-0.64) in the healthy controls, 0.35 (0.14-0.51) in the patients with compensated cirrhosis and 0.38 (0.13-0.77) in the patients with decompensated cirrhosis.",Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104076/),,0.35,106145,DB00927,Famotidine
,2104076,systemic availability,"The mean systemic availability of the drug, estimated from urinary recovery, was 0.39 (0.15-0.64) in the healthy controls, 0.35 (0.14-0.51) in the patients with compensated cirrhosis and 0.38 (0.13-0.77) in the patients with decompensated cirrhosis.",Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104076/),,0.38,106146,DB00927,Famotidine
,2871051,elimination half-life,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,72,106430,DB00927,Famotidine
,2871051,elimination half-life,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,55,106431,DB00927,Famotidine
,2871051,total area under the curve (AUC),"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],11.8,106432,DB00927,Famotidine
,2871051,total area under the curve (AUC),"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],9.8,106433,DB00927,Famotidine
,2871051,total clearance,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[ml] / [kg·min],0.20,106434,DB00927,Famotidine
,2871051,total clearance,"During the cimetidine as compared with the control treatment, diazepam elimination half-life was significantly increased (72 vs 55 hr, P less than .05), total area under the curve (AUC) increased (11.8 vs 9.8 hr-micrograms/mL, P less than .05), and total clearance reduced (0.20 vs 0.28 mL/min/kg, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[ml] / [kg·min],0.28,106435,DB00927,Famotidine
,2871051,AUC,"Seven-day AUC for desmethyldiazepam also increased (4.6 vs 3.8 hr-micrograms/mL, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],4.6,106436,DB00927,Famotidine
,2871051,AUC,"Seven-day AUC for desmethyldiazepam also increased (4.6 vs 3.8 hr-micrograms/mL, P less than .05).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],3.8,106437,DB00927,Famotidine
,2871051,elimination half-life,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,53,106438,DB00927,Famotidine
,2871051,elimination half-life,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),h,55,106439,DB00927,Famotidine
,2871051,total AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],9.5,106440,DB00927,Famotidine
,2871051,total AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],9.8,106441,DB00927,Famotidine
,2871051,total clearance,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[ml] / [kg·min],0.28,106442,DB00927,Famotidine
,2871051,AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],3.9,106443,DB00927,Famotidine
,2871051,AUC,"However, there were no significant differences between famotidine and control treatment conditions in diazepam elimination half-life (53 vs 55 hr), total AUC (9.5 vs 9.8 hr-micrograms/mL), or total clearance (0.28 vs 0.28 mL/min/kg) or in seven-day AUC for desmethyldiazepam (3.9 vs 3.8 hr-micrograms/mL).","Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2871051/),[hr-μgrams] / [ml],3.8,106444,DB00927,Famotidine
,8612382,area under the curve (AUC),"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),[h·μM] / [l],20.8,108097,DB00927,Famotidine
,8612382,area under the curve (AUC),"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),[h·μM] / [l],23.4,108098,DB00927,Famotidine
,8612382,peak,"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),,5,108099,DB00927,Famotidine
,8612382,peak,"Coingestion of a ferrous sulfate tablet with cimetidine (300 mg) was associated with little reduction in serum cimetidine area under the curve (AUC) (mean versus mean, 20.8 versus 23.4 mumol.hr/L; mean percentage difference, -11%; 95% confidence interval [CI] of percentage difference, -26% to 4.2%) or peak concentration (Cmax) (mean versus mean, 5.1 versus 6.1 mumol/L; mean percentage difference, -16%; CI of percentage difference, -36% to 4%).",Ferrous sulfate does not reduce serum levels of famotidine or cimetidine after concurrent ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612382/),,6,108100,DB00927,Famotidine
,28516414,oral bioavailability,Famotidine (FMT) has low oral bioavailability of 40-45% and short half-life between 2.5 to 4 h.,Optimized Mucoadhesive Coated Niosomes as a Sustained Oral Delivery System of Famotidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516414/),%,40-45,113063,DB00927,Famotidine
,28516414,half-life,Famotidine (FMT) has low oral bioavailability of 40-45% and short half-life between 2.5 to 4 h.,Optimized Mucoadhesive Coated Niosomes as a Sustained Oral Delivery System of Famotidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516414/),h,2.5 to 4,113064,DB00927,Famotidine
,2891370,maximum plasma concentration (Cmax),Coadministration of the antacid caused a small but significant reduction in the maximum plasma concentration (Cmax) of famotidine from 81.1 +/- 54.2 to 60.8 +/- 21.6 ng ml-1 (P less than 0.05) and a small decrease in the area under plasma concentration-time curve [AUC] from 443.3 +/- 249.2 to 355.0 +/- 125.1 ng ml-1 h (P greater than 0.05).,Effects of antacids and food on absorption of famotidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891370/),[ng] / [ml],81.1,118066,DB00927,Famotidine
,2891370,maximum plasma concentration (Cmax),Coadministration of the antacid caused a small but significant reduction in the maximum plasma concentration (Cmax) of famotidine from 81.1 +/- 54.2 to 60.8 +/- 21.6 ng ml-1 (P less than 0.05) and a small decrease in the area under plasma concentration-time curve [AUC] from 443.3 +/- 249.2 to 355.0 +/- 125.1 ng ml-1 h (P greater than 0.05).,Effects of antacids and food on absorption of famotidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891370/),[ng] / [ml],60.8,118067,DB00927,Famotidine
,2891370,area under plasma concentration-time curve [AUC],Coadministration of the antacid caused a small but significant reduction in the maximum plasma concentration (Cmax) of famotidine from 81.1 +/- 54.2 to 60.8 +/- 21.6 ng ml-1 (P less than 0.05) and a small decrease in the area under plasma concentration-time curve [AUC] from 443.3 +/- 249.2 to 355.0 +/- 125.1 ng ml-1 h (P greater than 0.05).,Effects of antacids and food on absorption of famotidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891370/),[h·ng] / [ml],443.3,118068,DB00927,Famotidine
,2891370,area under plasma concentration-time curve [AUC],Coadministration of the antacid caused a small but significant reduction in the maximum plasma concentration (Cmax) of famotidine from 81.1 +/- 54.2 to 60.8 +/- 21.6 ng ml-1 (P less than 0.05) and a small decrease in the area under plasma concentration-time curve [AUC] from 443.3 +/- 249.2 to 355.0 +/- 125.1 ng ml-1 h (P greater than 0.05).,Effects of antacids and food on absorption of famotidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891370/),[h·ng] / [ml],355.0,118069,DB00927,Famotidine
,2891370,Cmax,"However, there was only a minimal effect of food on these parameters; the Cmax and [AUC] were 81.6 +/- 29.6 ng ml-1 and 434.8 +/- 145.9 ng ml-1 h, respectively.",Effects of antacids and food on absorption of famotidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891370/),[ng] / [ml],81.6,118070,DB00927,Famotidine
,2891370,[AUC],"However, there was only a minimal effect of food on these parameters; the Cmax and [AUC] were 81.6 +/- 29.6 ng ml-1 and 434.8 +/- 145.9 ng ml-1 h, respectively.",Effects of antacids and food on absorption of famotidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891370/),[h·ng] / [ml],434.8,118071,DB00927,Famotidine
,8932543,maximum serum concentration (Cmax),"The mean (+/- SD) maximum serum concentration (Cmax) was 527.6 +/- 281.2 ng/mL, the elimination half-life (t1/2) was 3.2 +/- 3.0 hours, and the apparent steady-state volume of distribution (Vdss) was 2.4 +/- 1.7 L/kg.",Pharmacokinetics and pharmacodynamics of famotidine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932543/),[ng] / [ml],527.6,120332,DB00927,Famotidine
,8932543,elimination half-life (t1/2),"The mean (+/- SD) maximum serum concentration (Cmax) was 527.6 +/- 281.2 ng/mL, the elimination half-life (t1/2) was 3.2 +/- 3.0 hours, and the apparent steady-state volume of distribution (Vdss) was 2.4 +/- 1.7 L/kg.",Pharmacokinetics and pharmacodynamics of famotidine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932543/),h,3.2,120333,DB00927,Famotidine
,8932543,apparent steady-state volume of distribution (Vdss),"The mean (+/- SD) maximum serum concentration (Cmax) was 527.6 +/- 281.2 ng/mL, the elimination half-life (t1/2) was 3.2 +/- 3.0 hours, and the apparent steady-state volume of distribution (Vdss) was 2.4 +/- 1.7 L/kg.",Pharmacokinetics and pharmacodynamics of famotidine in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932543/),[l] / [kg],2.4,120334,DB00927,Famotidine
,8932543,Plasma clearance (Cl),"Plasma clearance (Cl) and renal clearance (ClR) were 0.70 +/- 0.34 L/hr/kg and 0.43 +/- 0.24 L/hr/kg, respectively.",Pharmacokinetics and pharmacodynamics of famotidine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932543/),[l] / [h·kg],0.70,120335,DB00927,Famotidine
,8932543,renal clearance (ClR),"Plasma clearance (Cl) and renal clearance (ClR) were 0.70 +/- 0.34 L/hr/kg and 0.43 +/- 0.24 L/hr/kg, respectively.",Pharmacokinetics and pharmacodynamics of famotidine in children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932543/),[l] / [h·kg],0.43,120336,DB00927,Famotidine
,2568929,urinary recovery of unchanged drug,Mean urinary recovery of unchanged drug up to 24 h in the young volunteers was 44%.,Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568929/),%,44,121392,DB00927,Famotidine
,2568929,renal clearance,"The mean renal clearance of famotidine in the young volunteers (270 ml.min-1) was substantially greater than the creatinine clearance, 128 ml.min-1, which suggests the possibility of tubular secretion of famotidine.",Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568929/),[ml] / [min],270,121393,DB00927,Famotidine
,8314361,t1/2 beta,The mean t1/2 beta of naproxen in 6 subjects was 25.7 +/- 5.4 h (range 16 to 36).,"The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,25.7,124746,DB00927,Famotidine
,8314361,t1/2 beta,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,25,124747,DB00927,Famotidine
,8314361,t1/2 beta,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,13,124748,DB00927,Famotidine
,8314361,t1/2 alpha,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,4.0,124749,DB00927,Famotidine
,8314361,t1/2 alpha,"Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h.","The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314361/),h,1.1,124750,DB00927,Famotidine
,24258773,Ratio of AUC pH to AUC drug concentration 0-12 hours,Ratio of AUC pH to AUC drug concentration 0-12 hours after first dose was significantly greater for famotidine (0.06849 ± 0.01460 SD) than ranitidine (0.02453 ± 0.01448; p < 0.001) demonstrating greater potency of famotidine.,Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258773/),,0.06849,133286,DB00927,Famotidine
,24258773,Ratio of AUC pH to AUC drug concentration 0-12 hours,Ratio of AUC pH to AUC drug concentration 0-12 hours after first dose was significantly greater for famotidine (0.06849 ± 0.01460 SD) than ranitidine (0.02453 ± 0.01448; p < 0.001) demonstrating greater potency of famotidine.,Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24258773/),,0.02453,133287,DB00927,Famotidine
,2888738,initial half-life (t1/2),After intravenous administration plasma levels declined biexponentially with an initial half-life (t1/2) of 0.5 h and a terminal t1/2 of 4.0 h.,Pharmacokinetics of famotidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888738/),h,0.5,133471,DB00927,Famotidine
,2888738,terminal t1/2,After intravenous administration plasma levels declined biexponentially with an initial half-life (t1/2) of 0.5 h and a terminal t1/2 of 4.0 h.,Pharmacokinetics of famotidine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888738/),h,4.0,133472,DB00927,Famotidine
,2888738,distribution volume,F was slightly bound to plasma proteins (less than 1 to 15%) and its distribution volume averaged 1.13 l/kg.,Pharmacokinetics of famotidine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888738/),[l] / [kg],1.13,133473,DB00927,Famotidine
,2888738,total plasma Cl,"Thus, hepatic clearance contributes to the total plasma Cl of 309 ml/min only 88 ml/min.",Pharmacokinetics of famotidine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888738/),[ml] / [min],309,133474,DB00927,Famotidine
,2888738,total plasma Cl,"Thus, hepatic clearance contributes to the total plasma Cl of 309 ml/min only 88 ml/min.",Pharmacokinetics of famotidine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888738/),[ml] / [min],88,133475,DB00927,Famotidine
,2888738,maximum plasma concentrations,Following oral administration maximum plasma concentrations of 104 +/- 39 ng/ml (mean +/- SD) were observed after 2.3 +/- 1 h.,Pharmacokinetics of famotidine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888738/),[ng] / [ml],104,133476,DB00927,Famotidine
,2888738,t1/2,F was eliminated with a t1/2 of 3.6 +/- 1.1 h and its absolute bioavailability ranged from 20 to 66%.,Pharmacokinetics of famotidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888738/),h,3.6,133477,DB00927,Famotidine
,2888738,absolute bioavailability,F was eliminated with a t1/2 of 3.6 +/- 1.1 h and its absolute bioavailability ranged from 20 to 66%.,Pharmacokinetics of famotidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888738/),%,20 to 66,133478,DB00927,Famotidine
,8573949,times to maximum cy,"The average times to maximum cyclosporine concentrations were similar between baseline (3.2 h), cimetidine (2.9 h), and famotidine (3.6 h) dosing periods.",Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573949/),h,3.2,139511,DB00927,Famotidine
,8573949,times to maximum cy,"The average times to maximum cyclosporine concentrations were similar between baseline (3.2 h), cimetidine (2.9 h), and famotidine (3.6 h) dosing periods.",Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573949/),h,2.9,139512,DB00927,Famotidine
,8573949,times to maximum cy,"The average times to maximum cyclosporine concentrations were similar between baseline (3.2 h), cimetidine (2.9 h), and famotidine (3.6 h) dosing periods.",Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573949/),h,3.6,139513,DB00927,Famotidine
,21770762,90% maximum effect (EC(90)),"However, all individual atazanavir C(min) values remained at least five-fold above the population mean protein-binding adjusted 90% maximum effect (EC(90)) against wild-type HIV (14 ng/mL).",Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21770762/),[ng] / [ml],14,142113,DB00927,Famotidine
,2303581,area under the serum famotidine concentration-time curve up to 10 hours,The mean area under the serum famotidine concentration-time curve up to 10 hours was increased by coadministration of probenecid from 424 +/- 19 (SEM) to 768 +/- 39 ng.hr/ml.,"The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303581/),[h·ng] / [ml],424,142774,DB00927,Famotidine
,2303581,area under the serum famotidine concentration-time curve up to 10 hours,The mean area under the serum famotidine concentration-time curve up to 10 hours was increased by coadministration of probenecid from 424 +/- 19 (SEM) to 768 +/- 39 ng.hr/ml.,"The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303581/),[h·ng] / [ml],768,142775,DB00927,Famotidine
,2303581,tubular secretion clearance,The mean tubular secretion clearance of famotidine was decreased from 196.2 +/- 21.4 to 22.0 +/- 4.2 ml/min.,"The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303581/),[ml] / [min],196.2,142776,DB00927,Famotidine
,2303581,tubular secretion clearance,The mean tubular secretion clearance of famotidine was decreased from 196.2 +/- 21.4 to 22.0 +/- 4.2 ml/min.,"The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303581/),[ml] / [min],22.0,142777,DB00927,Famotidine
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,6,146832,DB00927,Famotidine
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,8,146833,DB00927,Famotidine
,8097364,durations of action,"The durations of action of cimetidine, ranitidine, and famotidine are similar to the dosage intervals usually chosen (6, 8, and 12 hours, respectively).",Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097364/),h,12,146834,DB00927,Famotidine
,19853541,total run time,The total run time was 7 min per sample.,A single LC-tandem mass spectrometry method for the simultaneous determination of four H2 antagonists in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19853541/),[min] / [sample],7,146976,DB00927,Famotidine
,2882981,maximum rate of secretory transport (Tm),The maximum rate of secretory transport (Tm) of famotidine averaged 180 micrograms/min/kg.,Urinary excretion kinetics of famotidine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882981/),[μg] / [kg·min],180,158928,DB00927,Famotidine
,3429684,terminal elimination half-life,"The terminal elimination half-life was prolonged in Group 3 (18.6 +/- 5.7 hr) compared with Groups 1 (9.3 +/- 2.3 hr) and 2 (9.7 +/- 1.7 hr), P less than .05.",Disposition of famotidine in renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429684/),h,18.6,159160,DB00927,Famotidine
,3429684,terminal elimination half-life,"The terminal elimination half-life was prolonged in Group 3 (18.6 +/- 5.7 hr) compared with Groups 1 (9.3 +/- 2.3 hr) and 2 (9.7 +/- 1.7 hr), P less than .05.",Disposition of famotidine in renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429684/),h,9.3,159161,DB00927,Famotidine
,3429684,terminal elimination half-life,"The terminal elimination half-life was prolonged in Group 3 (18.6 +/- 5.7 hr) compared with Groups 1 (9.3 +/- 2.3 hr) and 2 (9.7 +/- 1.7 hr), P less than .05.",Disposition of famotidine in renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429684/),h,9.7,159162,DB00927,Famotidine
,3429684,Steady-state volume of distribution,Steady-state volume of distribution ranged from 0.80 to 1.26 L/kg but did not differ among the groups.,Disposition of famotidine in renal insufficiency. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429684/),[l] / [kg],0.80 to 1.26,159163,DB00927,Famotidine
,26538490,flow rate,"The flow rate was set at 1.0 mL min(-1), and the effluent was monitored by UV detector at 280 nm FAM and 320 nm for NIZ and RAN.",An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26538490/),[ml] / [min],1.0,164152,DB00927,Famotidine
,26538490,limits of detections,"The limits of detections and quantitations were 0.008-0.011 and 0.025-0.033 µg mL(-1), respectively.",An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26538490/),[μg] / [ml],0.008-0.011,164153,DB00927,Famotidine
,26538490,limits of detections,"The limits of detections and quantitations were 0.008-0.011 and 0.025-0.033 µg mL(-1), respectively.",An Efficient Ion-Pair Liquid Chromatographic Method for the Determination of Some H2 Receptor Antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26538490/),[μg] / [ml],0.025-0.033,164154,DB00927,Famotidine
,31089971,AUCinf,"Mean AUCinf at the 40 mg dose in the fasted state was 4,300 ± 1,083 ng·h/ml, which is 28% higher than the AUC reported following the administration of 90 (2 × 45) mg Rapamune® and 11% higher than the exposure reported for 25 mg intravenous pro-drug temsirolimus (3,810 ng·h/ml).",Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089971/),[h·ng] / [ml],"4,300",165393,DB00927,Famotidine
,31089971,AUCinf,"Mean AUCinf at the 40 mg dose in the fasted state was 4,300 ± 1,083 ng·h/ml, which is 28% higher than the AUC reported following the administration of 90 (2 × 45) mg Rapamune® and 11% higher than the exposure reported for 25 mg intravenous pro-drug temsirolimus (3,810 ng·h/ml).",Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31089971/),[h·ng] / [ml],"3,810",165394,DB00927,Famotidine
,8437966,plasma half-life,"Famotidine's plasma half-life (4.42 hrs) was significantly longer than ranitidine's (3.14 hrs, p < 0.05, paired t test).","Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437966/),h,4.42,167036,DB00927,Famotidine
,8437966,plasma half-life,"Famotidine's plasma half-life (4.42 hrs) was significantly longer than ranitidine's (3.14 hrs, p < 0.05, paired t test).","Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437966/),h,3.14,167037,DB00927,Famotidine
,8437966,duration of effect,"The duration of effect (defined as median pH > 4) was similar for ranitidine and famotidine, 10.3 and 9.9 hours, respectively (p = 0.713, paired Student's t test).","Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437966/),h,10.3,167038,DB00927,Famotidine
,8437966,duration of effect,"The duration of effect (defined as median pH > 4) was similar for ranitidine and famotidine, 10.3 and 9.9 hours, respectively (p = 0.713, paired Student's t test).","Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437966/),h,9.9,167039,DB00927,Famotidine
,2312768,ultrafiltration rate,"The mean (+/- SD) amount of the drug removed by the procedure, which was performed at the mean ultrafiltration rate of 19.0 +/- 6.0 ml/min over the mean duration of 212 +/- 168 min, corresponded to 4.1 +/- 2.2% of the daily maintenance doses.","Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312768/),[ml] / [min],19.0,167222,DB00927,Famotidine
,2312768,si,"There was a significant (r = 0.90, P less than .01) linear relationship between the hemofiltration clearance and the ultrafiltration rate, indicating that the sieving coefficient, an index filtration efficiency, for the drug was largely constant (i.e., 0.73 +/- 0.10) over the ranging filtration rates (i.e., 3.9-29.5 mL/min) employed in the present study.","Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312768/),,0.73,167223,DB00927,Famotidine
,2312768,filtration efficiency,"When the mean filtration efficiency of 0.73 obtained from the study is extrapolated into a 24-hour continuous arteriovenous hemofiltration performed at commonly used filtration rates (i.e., 6-12 ml/min), the 24-hour hemofiltration clearances are estimated to range from 4 to 9 ml/min.","Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312768/),,0.73,167224,DB00927,Famotidine
,2312768,clearances,"When the mean filtration efficiency of 0.73 obtained from the study is extrapolated into a 24-hour continuous arteriovenous hemofiltration performed at commonly used filtration rates (i.e., 6-12 ml/min), the 24-hour hemofiltration clearances are estimated to range from 4 to 9 ml/min.","Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312768/),[ml] / [min],4 to 9,167225,DB00927,Famotidine
,2312768,total body clearance,These clearance values are found to correspond to only 10 to 25% of the mean total body clearance (about 35 ml/min) reported from anuric patients.,"Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312768/),[ml] / [min],35,167226,DB00927,Famotidine
,11135083,renal clearances,"100 mg/L; renal clearances were 442 +/- 131 (mean +/- SD), 423 +/- 94, 233 +/- 45, and 152 +/- 18 mL/min/1.73 m2 at plasma concentrations of 18 +/- 2, 92 +/- 5, 291 +/- 47 and 789 +/- 28 mg/L, respectively.",Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135083/),[ml] / [1.73·m2·min],442,169934,DB00927,Famotidine
,11135083,renal clearances,"100 mg/L; renal clearances were 442 +/- 131 (mean +/- SD), 423 +/- 94, 233 +/- 45, and 152 +/- 18 mL/min/1.73 m2 at plasma concentrations of 18 +/- 2, 92 +/- 5, 291 +/- 47 and 789 +/- 28 mg/L, respectively.",Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135083/),[ml] / [1.73·m2·min],423,169935,DB00927,Famotidine
,11135083,renal clearances,"100 mg/L; renal clearances were 442 +/- 131 (mean +/- SD), 423 +/- 94, 233 +/- 45, and 152 +/- 18 mL/min/1.73 m2 at plasma concentrations of 18 +/- 2, 92 +/- 5, 291 +/- 47 and 789 +/- 28 mg/L, respectively.",Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135083/),[ml] / [1.73·m2·min],233,169936,DB00927,Famotidine
,11135083,renal clearances,"100 mg/L; renal clearances were 442 +/- 131 (mean +/- SD), 423 +/- 94, 233 +/- 45, and 152 +/- 18 mL/min/1.73 m2 at plasma concentrations of 18 +/- 2, 92 +/- 5, 291 +/- 47 and 789 +/- 28 mg/L, respectively.",Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135083/),[ml] / [1.73·m2·min],152,169937,DB00927,Famotidine
,11135083,apparent affinity (Km),"The apparent affinity (Km) and maximum secretory capacity (TmPAH) were 141 +/- 70 mg/L and 71 +/- 16 mg/min/1.73 m2, respectively.",Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135083/),[mg] / [l],141,169938,DB00927,Famotidine
,11135083,maximum secretory capacity (TmPAH),"The apparent affinity (Km) and maximum secretory capacity (TmPAH) were 141 +/- 70 mg/L and 71 +/- 16 mg/min/1.73 m2, respectively.",Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135083/),[mg] / [1.73·m2·min],71,169939,DB00927,Famotidine
,11135083,unbound renal clearance,"The unbound renal clearance and tubular secretory clearance of famotidine were 384 +/- 70 and 329 +/- 78 mL/min/1.73 m2, respectively, and were not significantly correlated with the unbound plasma concentrations, which ranged from 126 to 2659 ng/mL.",Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135083/),[ml] / [1.73·m2·min],384,169940,DB00927,Famotidine
,11135083,tubular secretory clearance,"The unbound renal clearance and tubular secretory clearance of famotidine were 384 +/- 70 and 329 +/- 78 mL/min/1.73 m2, respectively, and were not significantly correlated with the unbound plasma concentrations, which ranged from 126 to 2659 ng/mL.",Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135083/),[ml] / [1.73·m2·min],329,169941,DB00927,Famotidine
,11135083,unbound plasma concentrations,"The unbound renal clearance and tubular secretory clearance of famotidine were 384 +/- 70 and 329 +/- 78 mL/min/1.73 m2, respectively, and were not significantly correlated with the unbound plasma concentrations, which ranged from 126 to 2659 ng/mL.",Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135083/),[ng] / [ml],126 to 2659,169942,DB00927,Famotidine
up to,11135083,unbound plasma concentrations,The rate of tubular secretion was linear at unbound plasma concentrations up to 2659 ng/mL.,Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11135083/),[ng] / [ml],2659,169943,DB00927,Famotidine
,16046202,flow rate,"The mobile phase was a mixture of phosphate buffer (0.05 M) containing triethylamine (1 mL/L, v/v; pH 3.5) and methanol (91:9, v/v) at a flow rate of 2.2 mL/min.",High-performance liquid chromatographic determination of lamivudine in human serum using liquid-liquid extraction; application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046202/),[ml] / [min],2.2,171570,DB00927,Famotidine
,1764869,distribution half-life,"After intravenous administration the plasma famotidine concentration-time profile exhibits a biexponential decay, with a distribution half-life of about 0.18 to 0.5h and an elimination half-life of about 2 to 4h.",Clinical pharmacokinetics of famotidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),h,0.18 to 0.5,172321,DB00927,Famotidine
,1764869,elimination half-life,"After intravenous administration the plasma famotidine concentration-time profile exhibits a biexponential decay, with a distribution half-life of about 0.18 to 0.5h and an elimination half-life of about 2 to 4h.",Clinical pharmacokinetics of famotidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),h,2 to 4,172322,DB00927,Famotidine
,1764869,volume of distribution of the drug at steady-state,The volume of distribution of the drug at steady-state ranges from 1.0 to 1.3 L/kg; plasma protein binding is low (15 to 22%).,Clinical pharmacokinetics of famotidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),[l] / [kg],1.0 to 1.3,172323,DB00927,Famotidine
,1764869,plasma protein binding,The volume of distribution of the drug at steady-state ranges from 1.0 to 1.3 L/kg; plasma protein binding is low (15 to 22%).,Clinical pharmacokinetics of famotidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),%,15 to 22,172324,DB00927,Famotidine
,1764869,renal clearance,"Because its renal clearance (15 L/h) far exceeds the glomerular filtration rate, famotidine is considered to be eliminated not only via glomerular filtration but also via renal tubular secretion.",Clinical pharmacokinetics of famotidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),[l] / [h],15,172325,DB00927,Famotidine
,1764869,oral bioavailability,"After oral administration, peak plasma concentrations are attained within 2 to 4h; the oral bioavailability ranges from 40 to 50%, due mainly to incomplete absorption.",Clinical pharmacokinetics of famotidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1764869/),%,40 to 50,172326,DB00927,Famotidine
,27379272,absolute bioavailability,The absolute bioavailability of famotidine after oral administration is about 40-45% and absorbance only in the initial part of small intestine may be due to low intestinal permeability.,In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379272/),%,40-45,174238,DB00927,Famotidine
,27379272,permeation,In vitro drug permeation in intestine after 8 h for all formulations varied from 30.42% to 78.39% and most of the formulations showed enhanced permeation compared to pure drug (48.92%).,In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379272/),%,30.42,174239,DB00927,Famotidine
,27379272,permeation,In vitro drug permeation in intestine after 8 h for all formulations varied from 30.42% to 78.39% and most of the formulations showed enhanced permeation compared to pure drug (48.92%).,In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379272/),%,78.39,174240,DB00927,Famotidine
,27379272,permeation,In vitro drug permeation in intestine after 8 h for all formulations varied from 30.42% to 78.39% and most of the formulations showed enhanced permeation compared to pure drug (48.92%).,In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379272/),%,48,174241,DB00927,Famotidine
,27379272,C max,Famotidine microemulsion exhibited the higher absorption and C max⁡ achieved from the optimized famotidine formulation (456.20 ng·h/ml) was higher than the standard (126.80 ng·h/mL).,In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379272/),[h·ng] / [ml],456.20,174242,DB00927,Famotidine
,27379272,C max,Famotidine microemulsion exhibited the higher absorption and C max⁡ achieved from the optimized famotidine formulation (456.20 ng·h/ml) was higher than the standard (126.80 ng·h/mL).,In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379272/),[h·ng] / [ml],126.80,174243,DB00927,Famotidine
,27379272,AUC0-24 h,It was found that AUC0-24 h obtained from the optimized famotidine test formulation (3023.5 ng·h/mL) was significantly higher than the standard famotidine (1663.3 ng·h/mL).,In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379272/),[h·ng] / [ml],3023.5,174244,DB00927,Famotidine
,27379272,AUC0-24 h,It was found that AUC0-24 h obtained from the optimized famotidine test formulation (3023.5 ng·h/mL) was significantly higher than the standard famotidine (1663.3 ng·h/mL).,In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379272/),[h·ng] / [ml],1663.3,174245,DB00927,Famotidine
,27379272,T max,F-1 demonstrated a longer (6 h) T max⁡ compared with standard drug (2 h) and sustained the release of drug over 24 h.,In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27379272/),h,2,174246,DB00927,Famotidine
,24456044,T50%,"The optimized minitablets (F6) containing HPMC K4M (50.00%, w/w), Carbopol 971P (10.00%, w/w) and NaHCO3 (10.00%, w/w) were found to float in 1 min and remain lastingly buoyant over a period of 8 h in vitro, with excellent bioadhesive properties (20.81 g) and sustained drug release characteristics (T50% = 46.54%) followed one-order model.",Preparation of multiple-unit floating-bioadhesive cooperative minitablets for improving the oral bioavailability of famotidine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24456044/),%,46.54,179640,DB00927,Famotidine
,7863246,bioavailability,"Antacid ingestion decreased the bioavailability of famotidine, ranitidine and cimetidine by 20-25%, and the bioavailability of nizatidine by 12%.",Drug interactions of H2-receptor antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863246/),,12,179873,DB00927,Famotidine
,7846741,Volume of distribution,"Volume of distribution, elimination half-life, and area under the serum concentration-time curve were 1.52 +/- 0.37 l/kg, 2.29 +/- 0.38 h, and 1.14 +/- 0.32 ng.h/ml, respectively.",Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7846741/),[l] / [kg],1.52,181185,DB00927,Famotidine
,7846741,elimination half-life,"Volume of distribution, elimination half-life, and area under the serum concentration-time curve were 1.52 +/- 0.37 l/kg, 2.29 +/- 0.38 h, and 1.14 +/- 0.32 ng.h/ml, respectively.",Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7846741/),h,2.29,181186,DB00927,Famotidine
,7846741,area under the serum concentration-time curve,"Volume of distribution, elimination half-life, and area under the serum concentration-time curve were 1.52 +/- 0.37 l/kg, 2.29 +/- 0.38 h, and 1.14 +/- 0.32 ng.h/ml, respectively.",Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7846741/),[h·ng] / [ml],1.14,181187,DB00927,Famotidine
,7846741,oral bioavailability,The mean oral bioavailability of famotidine was 50.6%.,Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7846741/),%,50.6,181188,DB00927,Famotidine
,25495700,AUC0-∞,"The AUC0-∞ of famotidine gastric floating pellets (7776.52 ± 1065.93 h ng/ml) administered into rats was significantly higher than that of marketed rapid release tablets Xingfading® (Xingyi, Shanghai, China) (4166.23 ± 312.43 h ng/ml), while the relative bioavailability was 187.01 ± 22.81%.",Tablets compressed with gastric floating pellets coated with acrylic resin for gastro retention and sustained release of famotidine: in-vitro and in-vivo study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495700/),[h·ng] / [ml],7776.52,188369,DB00927,Famotidine
,25495700,AUC0-∞,"The AUC0-∞ of famotidine gastric floating pellets (7776.52 ± 1065.93 h ng/ml) administered into rats was significantly higher than that of marketed rapid release tablets Xingfading® (Xingyi, Shanghai, China) (4166.23 ± 312.43 h ng/ml), while the relative bioavailability was 187.01 ± 22.81%.",Tablets compressed with gastric floating pellets coated with acrylic resin for gastro retention and sustained release of famotidine: in-vitro and in-vivo study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495700/),[h·ng] / [ml],4166.23,188370,DB00927,Famotidine
,25495700,relative bioavailability,"The AUC0-∞ of famotidine gastric floating pellets (7776.52 ± 1065.93 h ng/ml) administered into rats was significantly higher than that of marketed rapid release tablets Xingfading® (Xingyi, Shanghai, China) (4166.23 ± 312.43 h ng/ml), while the relative bioavailability was 187.01 ± 22.81%.",Tablets compressed with gastric floating pellets coated with acrylic resin for gastro retention and sustained release of famotidine: in-vitro and in-vivo study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25495700/),%,187.01,188371,DB00927,Famotidine
,2892251,elimination half-life,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),h,35.3,195854,DB00927,Famotidine
,2892251,elimination half-life,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),h,37.3,195855,DB00927,Famotidine
,2892251,total plasma clearance,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),[ml] / [min],28.2,195856,DB00927,Famotidine
,2892251,total plasma clearance,"Nizatidine had no significant effect on the hepatic elimination of diazepam, as characterized by its elimination half-life (mean +/- SD) of 35.3 +/- 24.2 h (control) and 37.3 +/- 18.3 h (+ nizatidine) or its total plasma clearance of 28.2 +/-12.0 ml/min (control) and 26.7 +/- 10.4 ml/min (+ nizatidine).",Lack of effect of nizatidine on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892251/),[ml] / [min],26.7,195857,DB00927,Famotidine
,9231347,tubular transport maximum,A tubular transport maximum of 2400 +/- 220 micrograms min-1 and an apparent Michaelis-Menten constant for tubular secretion of 26 +/- 4 micrograms mL-1 (76 +/- 12 microM) were estimated from the curve.,Saturable urinary excretion kinetics of famotidine in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231347/),[μg] / [min],2400,204289,DB00927,Famotidine
,9231347,apparent Michaelis-Menten constant for tubular secretion,A tubular transport maximum of 2400 +/- 220 micrograms min-1 and an apparent Michaelis-Menten constant for tubular secretion of 26 +/- 4 micrograms mL-1 (76 +/- 12 microM) were estimated from the curve.,Saturable urinary excretion kinetics of famotidine in the dog. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231347/),[μg] / [ml],26,204290,DB00927,Famotidine
,9231347,apparent Michaelis-Menten constant for tubular secretion,A tubular transport maximum of 2400 +/- 220 micrograms min-1 and an apparent Michaelis-Menten constant for tubular secretion of 26 +/- 4 micrograms mL-1 (76 +/- 12 microM) were estimated from the curve.,Saturable urinary excretion kinetics of famotidine in the dog. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231347/),μM,76,204291,DB00927,Famotidine
>,7587962,aqueous solubility,"The aqueous solubility of L-735,524 was pH-dependent, > 100 mg/ml at pH below 3.5 and 0.03 mg/ml at pH 6.","pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587962/),[mg] / [ml],100,208875,DB00927,Famotidine
,7587962,aqueous solubility,"The aqueous solubility of L-735,524 was pH-dependent, > 100 mg/ml at pH below 3.5 and 0.03 mg/ml at pH 6.","pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587962/),[mg] / [ml],0.03,208876,DB00927,Famotidine
,7587962,bioavailability,"When L-735,524 was given orally as a suspension in 0.5% methocel (pH 6.5) at 10 mg/kg, the bioavailability was approximately 16% for both dogs and rats.","pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587962/),%,16,208877,DB00927,Famotidine
,7587962,bioavailability,"When the same dose of the drug was administered in 0.05 M citric acid (pH 2.5), the bioavailability increased 4.5-fold in dogs (72%), but only slightly in rats (24%).","pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587962/),%,72,208878,DB00927,Famotidine
,7587962,bioavailability,"When the same dose of the drug was administered in 0.05 M citric acid (pH 2.5), the bioavailability increased 4.5-fold in dogs (72%), but only slightly in rats (24%).","pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587962/),%,24,208879,DB00927,Famotidine
,19859791,relative bioavailability,"The in vivo study results clearly indicate the controlled and sustained release of Famotidine from the system, and the relative bioavailability of this preparation is about 1.605 in comparison to that of the marketed preparation.",A novel gastro-retentive osmotic pump capsule using asymmetric membrane technology: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19859791/),,1.605,211360,DB00927,Famotidine
,2340853,maximum serum concentration,Although the mean maximum serum concentration of famotidine during haemodialysis (141.5 ng.,Removal of famotidine by haemodialysis in elderly anuric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340853/),ng,141.5,212939,DB00927,Famotidine
,2890149,systemic availability,"The mean (+/- s.d.) systemic availability of the drug, estimated from the areas under the curves, was 36 +/- 24% in the control subjects and 46 +/- 24% in the patients with cirrhosis.",Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890149/),%,36,215498,DB00927,Famotidine
,2890149,systemic availability,"The mean (+/- s.d.) systemic availability of the drug, estimated from the areas under the curves, was 36 +/- 24% in the control subjects and 46 +/- 24% in the patients with cirrhosis.",Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890149/),%,46,215499,DB00927,Famotidine
,7657856,CL,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),[l] / [h],2.74,220019,DB00927,Famotidine
,7657856,CL,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),[l] / [h],2.07,220020,DB00927,Famotidine
,7657856,half-life,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),h,6.6 to 9.6,220021,DB00927,Famotidine
,7657856,mean residence time,"In contrast, cimetidine treatment significantly altered every pharmacokinetic parameter of theophylline as follows: Cimetidine decreased theophylline geometric mean CL from 2.74 L/h to 2.07 L/h (P < .001), and prolonged theophylline harmonic mean half-life from 6.6 to 9.6 hours (P < .001) and mean residence time from 10.8 to 15.0 hours (P < .001).",Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7657856/),h,10.8 to 15.0,220022,DB00927,Famotidine
,25476894,MTD,The MTD on the QD schedule was 150 mg.,"Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25476894/),mg,150,224219,DB00927,Famotidine
,2893637,total body clearance,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),[ml] / [min],57.6,224781,DB00927,Famotidine
,2893637,total body clearance,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),[ml] / [min],39.5,224782,DB00927,Famotidine
,2893637,half-life,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),h,8.7,224783,DB00927,Famotidine
,2893637,half-life,The mean total body clearance of theophylline was reduced from 57.6 ml min-1 before cimetidine to 39.5 ml min-1 during cimetidine; and the half-life was prolonged from 8.7 h before cimetidine to 12 h during cimetidine.,Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893637/),h,12,224784,DB00927,Famotidine
,2228341,plasma half-life,"However the plasma half-life of famotidine was slightly, but statistically significantly longer (p less than 0.05) during maintenance treatment with warfarin (mean +/- s.e.m.: 2.58 +/- 0.14 h versus 2.96 +/- 0.16 h respectively).",Lack of interaction between famotidine and warfarin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2228341/),h,2.58,230946,DB00927,Famotidine
,2228341,plasma half-life,"However the plasma half-life of famotidine was slightly, but statistically significantly longer (p less than 0.05) during maintenance treatment with warfarin (mean +/- s.e.m.: 2.58 +/- 0.14 h versus 2.96 +/- 0.16 h respectively).",Lack of interaction between famotidine and warfarin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2228341/),h,2.96,230947,DB00927,Famotidine
,24099279,Tmax,"During the fasting state, GDC-0941 was rapidly absorbed with a median Tmax of 2 h.",Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24099279/),h,2,237927,DB00927,Famotidine
,24099279,Tmax,"The presence of a high-fat meal delayed the absorption of GDC-0941, with a median Tmax of 4 h and a modest increase in AUC relative to the fasted state, with an estimated geometric mean ratio (GMR, 90% CI) of fed/fasted of 1.28 (1.08, 1.51) for AUC0-∞ and 0.87 (0.70, 1.06) for Cmax.",Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24099279/),h,4,237928,DB00927,Famotidine
,8186347,area under the plasma ethanol concentration-time curve (AUC0-t),"Famotidine increased the area under the plasma ethanol concentration-time curve (AUC0-t) by 29% (7.1 vs 5.5 mg.h/dL, P = 0.006) and maximal plasma concentration (Cmax) by 23% (9.2 vs 7.5 mg/dL, P = 0.013).",Famotidine increases plasma alcohol concentration in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8186347/),[h·mg] / [dl],7.1,242598,DB00927,Famotidine
,8186347,area under the plasma ethanol concentration-time curve (AUC0-t),"Famotidine increased the area under the plasma ethanol concentration-time curve (AUC0-t) by 29% (7.1 vs 5.5 mg.h/dL, P = 0.006) and maximal plasma concentration (Cmax) by 23% (9.2 vs 7.5 mg/dL, P = 0.013).",Famotidine increases plasma alcohol concentration in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8186347/),[h·mg] / [dl],5.5,242599,DB00927,Famotidine
,8186347,maximal plasma concentration (Cmax),"Famotidine increased the area under the plasma ethanol concentration-time curve (AUC0-t) by 29% (7.1 vs 5.5 mg.h/dL, P = 0.006) and maximal plasma concentration (Cmax) by 23% (9.2 vs 7.5 mg/dL, P = 0.013).",Famotidine increases plasma alcohol concentration in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8186347/),[mg] / [dl],9.2,242600,DB00927,Famotidine
,8186347,maximal plasma concentration (Cmax),"Famotidine increased the area under the plasma ethanol concentration-time curve (AUC0-t) by 29% (7.1 vs 5.5 mg.h/dL, P = 0.006) and maximal plasma concentration (Cmax) by 23% (9.2 vs 7.5 mg/dL, P = 0.013).",Famotidine increases plasma alcohol concentration in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8186347/),[mg] / [dl],7.5,242601,DB00927,Famotidine
,1781278,initial,"After 20 mg iv, plasma levels declined biexponentially with an initial T1/2 of 0.3 +/- 0.2 h and terminal T1/2 of 3.5 +/- 0.8 h.",Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781278/),h,0.3,242656,DB00927,Famotidine
,1781278,T1/2,"After 20 mg iv, plasma levels declined biexponentially with an initial T1/2 of 0.3 +/- 0.2 h and terminal T1/2 of 3.5 +/- 0.8 h.",Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781278/),h,0.3,242657,DB00927,Famotidine
,1781278,terminal T1/2,"After 20 mg iv, plasma levels declined biexponentially with an initial T1/2 of 0.3 +/- 0.2 h and terminal T1/2 of 3.5 +/- 0.8 h.",Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781278/),h,3.5,242658,DB00927,Famotidine
,1781278,plasma elimination T1/2,The plasma elimination T1/2 following po administration were 3.4 +/- 0.7 h and 3.5 +/- 0.5 h for capsules and tablets respectively.,Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781278/),h,3.4,242659,DB00927,Famotidine
,1781278,plasma elimination T1/2,The plasma elimination T1/2 following po administration were 3.4 +/- 0.7 h and 3.5 +/- 0.5 h for capsules and tablets respectively.,Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781278/),h,3.5,242660,DB00927,Famotidine
,1781278,absolute bioavailabilities,The absolute bioavailabilities were 38 +/- 10% for capsules and 43 +/- 11% for tablets.,Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781278/),%,38,242661,DB00927,Famotidine
,1781278,absolute bioavailabilities,The absolute bioavailabilities were 38 +/- 10% for capsules and 43 +/- 11% for tablets.,Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781278/),%,43,242662,DB00927,Famotidine
,1781278,renal,Mean renal and plasma clearance were 416 and 541 ml.min-1 respectively.,Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781278/),[ml] / [min],416,242663,DB00927,Famotidine
,1781278,plasma clearance,Mean renal and plasma clearance were 416 and 541 ml.min-1 respectively.,Pharmacokinetics and bioavailability of famotidine in 10 Chinese healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781278/),[ml] / [min],541,242664,DB00927,Famotidine
,22678358,total area under the total plasma concentration-time curve (AUC(0-12)),"Here, we report a patient treated with dasatinib and H2RA famotidine for whom the total area under the total plasma concentration-time curve (AUC(0-12)) of dasatinib dramatically increased after cessation of famotidine from 505.7 to 1,816.3 ng·h/mL.",H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678358/),[h·ng] / [ml],505.7,244961,DB00927,Famotidine
,22678358,total area under the total plasma concentration-time curve (AUC(0-12)),"Here, we report a patient treated with dasatinib and H2RA famotidine for whom the total area under the total plasma concentration-time curve (AUC(0-12)) of dasatinib dramatically increased after cessation of famotidine from 505.7 to 1,816.3 ng·h/mL.",H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678358/),[h·ng] / [ml],"1,816.3",244962,DB00927,Famotidine
,29572958,elimination half-life,The median (range) elimination half-life was 3.33 (3.21-3.54) hours.,Pharmacokinetics and efficacy of intravenous famotidine in adult cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572958/),h,3.33,258291,DB00927,Famotidine
,32671657,IC50,"In vitro studies demonstrated that PPIs inhibited rOAT3-mediated uptake of MTX, with estimated IC50 values of 2.1-5.2 μM, and a rank order of esomeprazole ≈ lansoprazole ≈ omeprazole > rabeprazole.",Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671657/),μM,2.1-5.2,258778,DB00927,Famotidine
,7650224,EC50,The plasma concentration of famotidine associated with 50% inhibition of pentagastrin stimulated gastric acid secretion (EC50; 10 ng/mL) was attained on average within 0.5 hours post-dose for the wafer and tablet.,Novel oral medication delivery system for famotidine. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650224/),[ng] / [ml],10,259307,DB00927,Famotidine
,23980865,gastric pH,The average gastric pH in fasted dogs ranged from 1.45 to 3.03.,Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23980865/),,1.45 to 3.03,265403,DB00927,Famotidine
,2311331,elimination half-life,Plasma famotidine concentrations declined with an elimination half-life of 3.3 +/- 1.8 h (mean +/- SD) and the drug was effective in elevating the gastric pH above 3.5 for about 9 hours in 6 patients.,Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311331/),h,3.3,272514,DB00927,Famotidine
,2311331,volume of distribution,"The variable volume of distribution and total plasma clearance of famotidine averaged 1.4 +/- 1.0 L/kg and 0.3 +/- 0.17 L/h/kg, respectively.",Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311331/),[l] / [kg],1.4,272515,DB00927,Famotidine
,2311331,total plasma clearance,"The variable volume of distribution and total plasma clearance of famotidine averaged 1.4 +/- 1.0 L/kg and 0.3 +/- 0.17 L/h/kg, respectively.",Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311331/),[l] / [h·kg],0.3,272516,DB00927,Famotidine
,2311331,amount excreted,The amount excreted (21 to 79%) correlated with clearance (r = 0.97).,Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311331/),%,21 to 79,272517,DB00927,Famotidine
